PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 88 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139 | -28.0% | 13,394 | -0.3% | 0.00% | – |
| Q2 2023 | $193 | +78.7% | 13,432 | -10.9% | 0.00% | – |
| Q1 2023 | $108 | -35.7% | 15,068 | +0.8% | 0.00% | – |
| Q4 2022 | $168 | -99.9% | 14,950 | +2.2% | 0.00% | – |
| Q3 2022 | $163,000 | +87.4% | 14,635 | +41.5% | 0.00% | – |
| Q2 2022 | $87,000 | -96.8% | 10,340 | -87.2% | 0.00% | – |
| Q4 2020 | $2,692,000 | -47.7% | 81,021 | -42.3% | 0.00% | -100.0% |
| Q3 2020 | $5,151,000 | -11.8% | 140,462 | -20.8% | 0.00% | 0.0% |
| Q2 2020 | $5,837,000 | – | 177,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |